Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Overall Study	STARTED	Mavrilimumab 10 mg	48
Overall Study	STARTED	Mavrilimumab 30 mg	49
Overall Study	STARTED	Mavrilimumab 50 mg	49
Overall Study	STARTED	Mavrilimumab 100 mg	48
Overall Study	STARTED	Placebo	96
Overall Study	COMPLETED	Mavrilimumab 10 mg	44
Overall Study	COMPLETED	Mavrilimumab 30 mg	47
Overall Study	COMPLETED	Mavrilimumab 50 mg	46
Overall Study	COMPLETED	Mavrilimumab 100 mg	45
Overall Study	COMPLETED	Placebo	82
Overall Study	NOT COMPLETED	Mavrilimumab 10 mg	4
Overall Study	NOT COMPLETED	Mavrilimumab 30 mg	2
Overall Study	NOT COMPLETED	Mavrilimumab 50 mg	3
Overall Study	NOT COMPLETED	Mavrilimumab 100 mg	3
Overall Study	NOT COMPLETED	Placebo	14

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01050998/flow